Nat Commun:DNA甲基化和肥胖之间的关系

2012-05-25 Beyond 生物谷

近日,在线发表在Nature Communications杂志上的一项研究论文中,四川农业大学和华大基因研究人员报道了猪脂肪及肌肉组织中的DNA甲基化信息,探究了DNA甲基化与肥胖之间的关系。 肥胖可以被视为一种流行病,在现代社会对人类健康有较大风险。肥胖已成为一些慢性疾病包括糖尿病、心血管疾病和癌症的一个重要的危险因素。据预测到2030年,全球成人人口中约58%的人可能超重或患有肥胖。 为了

近日,在线发表在Nature Communications杂志上的一项研究论文中,四川农业大学和华大基因研究人员报道了猪脂肪及肌肉组织中的DNA甲基化信息,探究了DNA甲基化与肥胖之间的关系。

肥胖可以被视为一种流行病,在现代社会对人类健康有较大风险。肥胖已成为一些慢性疾病包括糖尿病、心血管疾病和癌症的一个重要的危险因素。据预测到2030年,全球成人人口中约58%的人可能超重或患有肥胖。

为了迎接这一挑战,全世界的研究人员为获得肥胖基因做出了巨大努力。虽然DNA序列中包含的所有信息使我们每个人都不一样,但我们的行为和外观的许多细节实际上是由基因调控的。四川农业大学的Mingzhou Li教授说,为了促进肥胖的研究,有必要了解表观遗传因素,特别是在肥胖发展中扮演一个重要角色的DNA甲基化。

为了研究DNA甲基化与肥胖之间的关系。在这项研究中,研究人员把猪作为研究模型。共选择三类猪种包括长白猪,藏族和荣昌猪。在表观数据的基础上,研究人员构建了全基因组DNA甲基化图以及研究脂肪和肌肉所需的基因表达图谱。

四川农业大学Xuewei Li教授说,根据DNA甲基化相关的基因组数据,我们对ATs和SMTS进行了一个全面的全基因组的表观遗传研究,我相信我们的结果为探索脂肪沉积的表观机制和肌肉的生长奠定了坚实的基础。

doi:10.1038/ncomms1854
PMC:
PMID:

An atlas of DNA methylomes in porcine adipose and muscle tissues

Mingzhou Li,Honglong Wu,Zonggang Luo,Yudong Xia,Jiuqiang Guan,et al.

It is evident that epigenetic factors, especially DNA methylation, have essential roles in obesity development. Here, using pig as a model, we investigate the systematic association between DNA methylation and obesity. We sample eight variant adipose and two distinct skeletal muscle tissues from three pig breeds living within comparable environments but displaying distinct fat level. We generate 1,381 Gb of sequence data from 180 methylated DNA immunoprecipitation libraries, and provide a genome-wide DNA methylation map as well as a gene expression map for adipose and muscle studies. The analysis shows global similarity and difference among breeds, sexes and anatomic locations, and identifies the differentially methylated regions. The differentially methylated regions in promoters are highly associated with obesity development via expression repression of both known obesity-related genes and novel genes. This comprehensive map provides a solid basis for exploring epigenetic mechanisms of adipose deposition and muscle growth.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1879262, encodeId=360918e9262be, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 20 06:58:00 CST 2013, time=2013-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086614, encodeId=b813208661434, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Mar 22 08:58:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4355, encodeId=df68435554, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e50862410, createdName=chinadongrui, createdTime=Mon Jun 04 20:58:00 CST 2012, time=2012-06-04, status=1, ipAttribution=)]
    2013-03-20 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1879262, encodeId=360918e9262be, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 20 06:58:00 CST 2013, time=2013-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086614, encodeId=b813208661434, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Mar 22 08:58:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4355, encodeId=df68435554, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e50862410, createdName=chinadongrui, createdTime=Mon Jun 04 20:58:00 CST 2012, time=2012-06-04, status=1, ipAttribution=)]
    2013-03-22 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1879262, encodeId=360918e9262be, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 20 06:58:00 CST 2013, time=2013-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086614, encodeId=b813208661434, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Mar 22 08:58:00 CST 2013, time=2013-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=4355, encodeId=df68435554, content=真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e50862410, createdName=chinadongrui, createdTime=Mon Jun 04 20:58:00 CST 2012, time=2012-06-04, status=1, ipAttribution=)]
    2012-06-04 chinadongrui

    真好

    0

相关资讯

Clin Epi:西兰花抗癌又添新证据

DNA甲基化(DNA methylation)是最早发现的修饰途径之一,大量研究表明,DNA甲基化能引起染色质结构、DNA构象、DNA稳定性及DNA与蛋白质相互作用方式的改变,从而控制基因表达。DNA甲基化是关闭基因通道的正常操作过程,有助于调控细胞获取DNA基因信息。在癌症疾病中,DNA甲基化进程被打乱。其他一些疾病如心血管疾病、免疫功能低下、神经变性疾病等患者体内同样也存在着DNA甲基化进程紊